Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 12/20 | 0.38 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | ACACA | Q13085 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1676585 | 1.00 | ACLY (0.38) | ACLYSUV39H2KDM4ENPC1CRHBP | |
| SCHEMBL1676622 | 0.95 | SUV39H2 (0.36) | ACLYSUV39H2KDM4ENPC1CRHBP | |
| SCHEMBL1676627 | 0.95 | SUV39H2 (0.36) | ACLYSUV39H2KDM4ENPC1CRHBP | |
| SCHEMBL1676404 | 0.91 | ACLY (0.41) | ACLYSUV39H2KDM4ENPC1CRHBP | |
| SCHEMBL1676407 | 0.91 | ACLY (0.41) | ACLYSUV39H2KDM4ENPC1CRHBP | |
| SCHEMBL1676730 | 0.90 | DRD2 (0.39) | ACLY | |
| SCHEMBL1676728 | 0.90 | DRD2 (0.39) | ACLY | |
| SCHEMBL1676368 | 0.88 | KDM4E (0.39) | KDM4ENPC1CRHBPRAB9ACRHR2 | |
| SCHEMBL1676370 | 0.88 | KDM4E (0.39) | KDM4ENPC1CRHBPRAB9ACRHR2 | |
| SCHEMBL1676527 | 0.87 | RAB9A (0.37) | KDM4ENPC1CRHBPRAB9ACRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | TRANSTECH PHARMA, INC. (US) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | PTPRO, PTPN5, PTPRE | ACLY 1839/4885SUV39H2 3740/4885KDM4E 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.